Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase 2, Open-Label Study of the Safety and Efficacy of the Selective Inhibitor of Nuclear Export (SINE) Selinexor (KPT-330) in Patients With Advanced Squamous Cell Carcinoma of the Head and Neck, Lung, or Esophagus

Next Previous
X
Search
Trial Profile

A Phase 2, Open-Label Study of the Safety and Efficacy of the Selective Inhibitor of Nuclear Export (SINE) Selinexor (KPT-330) in Patients With Advanced Squamous Cell Carcinoma of the Head and Neck, Lung, or Esophagus

Status: Discontinued
Phase of Trial: Phase II

Latest Information Update: 30 Jan 2023

Price :

$35 *

Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Selinexor (Primary)
  • Indications Head and neck cancer; Lung cancer; Oesophageal cancer; Squamous cell cancer
  • Focus Therapeutic Use
  • Acronyms STARRS
  • Sponsors Karyopharm Therapeutics

    • Most Recent Events

    • 26 May 2016 Planned End Date changed from 1 Apr 2016 to 1 Jun 2016.
    • 23 Mar 2016 Status changed from active, no longer recruiting to discontinued as per ClinicalTrials.gov record.
    • 22 Feb 2016 Planned End Date changed from 1 Feb 2016 to 1 Mar 2016, according to ClinicalTrials.gov record.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top